Genzyme Osteopenia/Osteoporosis Study

Gaucher Disease Clinical Trial

Official title:

Prevalence of Gaucher Among Patients With Osteopenia/Osteoporosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02785744
• Other study ID #: 15-00351
• Status: Completed
• Start date: April 1, 2016
• Est. completion date: September 1, 2019

Study information

• Verified date: March 2021
• Source: NYU Langone Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Gaucher disease is a most common genetic metabolic disease characterized by low platelet number, liver and spleen enlargement and various forms of bone diseases including low bone mineral density leading to brittle bones. Various treatment options are now available for this disease. The purpose of this research study is to determine the prevalence of Gaucher disease in patients with low bone mineral density as observed by DEXA scan, which is a form of X-Ray of the bone.

Description:

Gaucher disease is a potential secondary cause of low bone mineral density and it is prevalent among patients with low BMD. This cross sectional design study will measure point prevalence of Gaucher disease in patients with low bone mineral density (BMD).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 76
• Est. completion date: September 1, 2019
• Est. primary completion date: September 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients > or equal to18 years and able to provide written consent.
• Patients who have had a bone density test demonstrating T-score <-1.0 on a DEXA scan within the past year or those who are prospectively referred for DEXA scan and who are later identified by their physician to have a DEXA T-score < -1.0.

Exclusion Criteria:

• Subject unable to read and sign consent form.
• Terminally ill subjects or subjects with serious co-morbidities (malignancy), which would limit the ability of the patient to participate in the study.
• Subjects with the following disorders or exposures
• Underlying skeletal dysplasia
• An endocrinologic/metabolic disease known to cause bone demineralization: including parathyroid dysfunction, hyperthyroidism, Cushing syndrome, hypogonadism, panhypopituitarism
• Cystic Fibrosis
• Exposure to medications that are known to cause low BMD including chemotherapy within past 2 years, chronic corticosteroid or phenytoin use within past 2 years
• Radiation exposure within the past 5 years
• Vitamin D deficiency is not an exclusion criteria as this is highly prevalent in the adult population under investigation as well as in patients with Gaucher disease. (9, 10)
• Subjects previously diagnosed with Gaucher Disease

Related Conditions & MeSH terms

• Bone Diseases, Metabolic
• Gaucher Disease
• Osteoporosis

Intervention

Other:
• Gaucher disease DNA mutation analysis

Locations

Country	Name	City	State
United States	New York University School of Medicine	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
NYU Langone Health	Genzyme, a Sanofi Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Population prevalence of Gaucher disease among patients with low bone mineral density		2 Years